Plain-language summaries of the published literature on the compounds we sell — written for laboratory reference, not as medical guidance. Every article ends with a research-use-only disclaimer because that is the only context in which this material applies.
How research peptides degrade, what slows it down, and the temperature, light, and freeze-thaw considerations that determine whether a vial stays viable for weeks or months in a research setting.
How lyophilized peptide vials behave when rehydrated, why bacteriostatic water exists, and the laboratory-handling considerations researchers use to preserve compound integrity.
A profile of Melanotan-2: the cyclic α-MSH analog, its non-selective melanocortin receptor activity, and how it differs from Melanotan I and PT-141.
A profile of ipamorelin: the pentapeptide ghrelin-receptor agonist that releases growth hormone without the cortisol spikes of the older GHRPs.
A lab-reference profile of NAD+: the redox coenzyme's structure, why it degrades so fast in solution, its inverse pH stability, and the precursor debate.
What GLP-3 RT is at the molecular level: the GIP/GLP-1/glucagon triple agonist known in the literature as retatrutide, its lipidation, half-life, and handling.
A profile of tesamorelin: the GHRH(1-44) analog with an N-terminal hexenoyl cap, how its half-life and stability compare to CJC-1295, and handling notes.
An overview of the GHK-Cu literature: the tripeptide-copper complex, why the blue color matters analytically, and the copper-specific handling rules.
What TB-500 actually is at the molecular level, the actin-binding mechanism behind the literature, and the storage rules for a 43-amino-acid peptide.
An overview of the BPC-157 literature, the molecule's structural features, what is known about its stability under different conditions, and laboratory-handling notes for research use.
Semax and Selank share a Pro-Gly-Pro tail but descend from different parents — ACTH and tuftsin. How the two compare in structure, mechanism, and storage.
How BPC-157 and TB-500 differ in mechanism and research-design context, where their literatures overlap, and how to read combination-protocol papers.
What the drug-affinity complex (DAC) modification actually does to CJC-1295, how it changes the molecule's plasma half-life, and the experimental-design implications for research work.
HelixCore Biotech
Den här webbplatsen innehåller forskningsmaterial. Genom att gå in bekräftar du att du är 18 år eller äldre och accepterar våra villkor samt RUO-friskrivningen.